Top biotech company
Overall rank: 4
2009 revenue: $4.4 billion
Biogen Idec. boasts three drugs – Avonex, Rituxan, and Tysabri – that all rang up sales of more than $1 billion last year. "Very few companies can say they have three blockbuster products," said Paul J. Clancy (right), chief financial officer of the company.
Biogen has enjoyed six consecutive years of double-digit increases in earnings per share, and saw its net income increase 23.9 percent in 2009 on revenue of $4.38 billion.